Promising Antiviral Glyco-Molecules from an Edible Alga

Combating the Threat of Pandemic Influenza: Drug Discovery Approaches

Volumn , Issue , 2007, Pages 166-182

  Hayashi, Toshimitsu ^a   Hayashi, Kyoko ^a   Kanekiyo, Kenji ^a   Ohta, Yuko ^a   Lee, Jung Bum ^a   Hashimoto, Minoru ^b   Nakano, Takahisa ^b  

^a UNIVERSITY OF TOYAMA   (Japan)

^b RIKEN VITAMIN CO LTD   (Japan)

Author keywords

Fucoidan and oseltamivir in virus replication inhibition; Fucoidan effects on immune system; in vitro anti influenza virus fucoidan activity

Indexed keywords

EID: 84889834341     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470179727.ch7     Document Type: Chapter

References (49)

1. Lui, K. J.; Kendal, A. P. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am. J. Public Health 1987, 77, 712-176.
2. Yuen, K. Y.; Chan, P. K.; Peiris, M.; Tsang, D. N.; Que, T. L.; Shortridge, K. F.; Cheung, P. T.; To, W. K.; Ho, E. T.; Sung, R.; Cheng, A. F. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998, 351, 467-471.
3. Subbarao, K.; Klimov, A.; Katz, J.; Regnery, H.; Lim, W.; Hall, H.; Perdue, M.; Swayne, D.; Bender, C.; Huang, J.; Hemphil, M.; Rowe, T.; Shaw, M.; Xu, X.; Fukuda, K.; Cox, N. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fetal respiratory illness. Science 1998, 279, 393-396.
4. Claas, E. C.; Osterhaus, A. D.; van Beek, R.; De Jong, J. C.; Rimmelzwaan, G. F.; Senne, D. A.; Krauss, S.; Shortridge, K. F.; Webster, R. G. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998, 351, 472-477.
5. Hayden, F. G.; Treanor, J. J.; Fritz, R. S.; Lobo, M.; Betts, R. F.; Miller, M.; Kinnersley, N.; Mills, R. G.; Ward, P.; Straus, S. E. Use of the oral NA inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment. JAMA 1999, 282, 1240-1246.
6. Nicholson, K. G.; Aoki, F. Y.; Osterhaus, A. D.; Trottier, S.; Carewicz, O.; Mercier, C. H.; Rode, A.; Kinnersley, N.; Ward, P. Efficacy and safety of oseltamivir in treatment of acute influenza: A randomised controlled trial. Lancet 2000, 355, 1845-1850.
7. Hayden, F. G.; Osterhaus, A. D.; Treanor, J. J.; Fleming, D. M.; Aoki, F. Y.; Nicholson, K. G.; Bohnen, A. M.; Hirst, H. M.; Keene, O.; Wightman, K. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infection. N. Engl. J. Med. 1997, 337, 874-880.
8. Mist Study Group. Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998, 352, 1877-1881.
9. Monto, A. S.; Fleming, D. M.; Henry, D.; de Groot, R.; Makela, M.; Klein, T.; Eliott, M.; Keene, O. N.; Man, C. Y. Efficacy and safety ofthe neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J. Infect. Dis. 1999, 180, 254-261.
10. Kiso, M.; Mitamura, K.; Sakai-Tagawa, Y.; Shiraishi, K.; Kawakami, C.; Kimura, K.; Hayden, F. G.; Sugaya, N.; Kawaoka, Y. Resistant influenza A viruses in children treated with oseltamivir: Descriptive study. Lancet 2004, 264, 759-765.
11. Zambon, M.; Hayden, F. G. Position statement: Global neuraminidase inhibitor susceptibility network. Antiviral Res. 2001, 49, 147-156.
12. Hayden, F. G. Perspectives on antiviral use during pandemic influenza. Phil. Trans. R. Soc. Lond. 2001, 356, 1877-1884.
13. Gubareva, L.V.; Kaiser, L.; Metrosovich, M. N.; Soo-Hoo, Y.; Hayden, F. G. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 2001, 183, 523-531.
14. Ison, M. G.; Gubareva, L.V.; Atmar, R. L.; Treanor, J.; Hayden, F. G. Recovery of drug-resistant influenza virus from immunocompromised patients: A case series. J. Infect. Dis. 2006, 193, 760-764.
15. Ison, M. G.; Mishin, V. P.; Braciale, T. J.; Hayden, F. G.; Gubareva, L. V. Comparative activities of oseltamivir and A-322278 in immunocmpetent and immunocompromised murine models of influenza virus infection. J. Infect. Dis. 2006, 193, 765-772.
16. Hosoya, M.; Balzarini, J.; Shigeta, S.; De Clercq, E. Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins. Antimicrob. Agents Chemother. 1991, 35, 2515-2520.
17. Hosoya, M.; Shigeta, S.; Ishii, T.; Suzuki, H.; De Clercq, E. Comparative inhibitory effects of various nucleoside and nonnucleoside analogues on replication of influenza virus types A and B in vitro and in ovo. J. Infect. Dis. 1993, 168, 641-646.
18. Lee, J. B.; Hayashi, K.; Hashimoto, M.; Nakano, T.; Hayashi, T. Novel antiviral fucoidan from sporophyll of Undaria pinnatifia (Mekabu). Chem. Pharm. Bull. 2004, 52, 1091-1094.
19. Itoh, H.; Noda, H.; Amano, H.; Zuaug, C.; Mizuno, T.; Ito, H. Antitumor activity and immunological properties of marine algal polysaccharides, especially fucoidan, prepared from Sargassum thunbergii of Phaeophy-ceae. Anticancer Res. 1993, 13, 2045-2052.
20. Itoh, H.; Noda, H.; Amano, H.; Itoh, H. Immunological analysis of inhibition of lung metastases by fucoidan (GIV-A) prepared from brown seaweed Sargassum thunbergii. Anticancer Res. 1995, 15, 1937-1948.
21. Okai, Y.; Higashi-Okai, K.; Ishizuka, S.; Ohtani, K.; Matzui-Yuasa, I.; Yamashita, U. Possible immunomodulating activities in an extract of edible brown alga, Hijikia fusiforme (Hijiki). J. Sci. Food. Agric. 1998, 76, 56-62.
22. Shan, B. E.; Yoshida, Y.; Kuroda, E.; Yamashita, U. Immunomodulating activity of seaweed extract on human lymphocytes in vitro. Int. J. Immu-nopharmacol. 1999, 21, 59-70.
23. Liu, J.N.; Yoshida, Y.; Wang, M.Q.; Okai, Y.; Yamashita, U. Bcellstimulating activity of seaweed extracts. Int. J. Immunopharmacol. 1997, 19, 135-142.
24. Wilson, S. Z.; Knight, V.; Wyde, P. R.; Drake, S.; Couch, R. B. Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob. Agents Chemother. 1980, 17, 642-648.
25. Hayden, F. G. Combinations of antiviral agents for treatment of influenza virus infections. J. Antimicrob. Chemother. 1986, 18 (Suppl. B), 77-83.
26. Zhirnov, O. P. High protection of animals lethally infected with influenza virus by aprotinin-rimantadine combination. J. Med. Virol. 1987, 21, 161-167.
27. Sidwell, R. W.; Smee, D. F.; Huffman, J. H.; Barnard, D. L.; Bailey, K. W.; Morrey, J. D.; Babu, Y. S. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RWJ-270201. Antimicrob. Agents Chemother. 2001, 45, 749-757.
28. Smee, D. F.; Bailey, K. W.; Morrison, A. C.; Sidwell, R. W. Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemother. 2002, 48, 88-93.
29. Govorkova, E. A.; Fang, H. B.; Tan, M.; Webster, R. G. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic antiinfluenza virus effects in MDCK cells. Antimicrob. Agents Chemother. 2004, 48, 4855-4863.
30. Sugawara, I.; Ishizaka, S. Polysaccharides with sulfate groups are human T-cell mitogens and murine polyclonal B-cell activators (PBAs). Cellular Immunol. 1982, 74, 162-171.
31. Baba, M.; Snoeck, R.; Pauwels, R.; De Clercq, E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalvirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob. Agents Chemother. 1988, 32, 1742-1745.
32. Lüscher-Mattli, M.; Gluck, R. Dextran sulfate inhibits the fusion of influenza virus with model membranes, and suppresses influenza virus replication in vivo. Antiviral Res. 1990, 14, 39-50.
33. Akaike, T.; Weihe, E.; Schaefer, M.; Fu, Z. F.; Zheng, Y. M.; Vogel, W.; Schmidt, H.; Koprowski, H. Effect of neurotropic virus infection on neuronal and inducible nitric oxide synthase activity in rat brain. J. Neurovirol. 1995, 1, 118-125.
34. Akaike, T.; Noguchi, Y.; Ijiri, S.; Setoguchi, K.; Suga, M.; Zeng, Y. M.; Dietzscold, B.; Maeda, H. Pathogenesis of influenza virus-induced pneumonia involvement of both nitric oxide and oxygen radicals. Proc. Natl. Acad. Sci. USA 1996, 93, 2448-2453.
35. Mikami, S.; Kawashima, S.; Kanazawa, K.; Hirata, K.; Katayama, Y.; Hotta, H.; Hayashi, Y.; Ito, H.; Yokoyama, M. Expression of nitric oxide synthase in a murine model of viral myocarditis induced by coxsackievirus B3. Biochem. Biophys. Res. Commun. 1996, 220, 983-989.
36. Fujii, S.; Akaike, T.; Maeda, H. Role of nitric oxide in pathogenesis of herpes simplex virus encephalitis in rats. Virology 1999, 256, 203-212.
37. Bukowski, L. K.; Woda, B. A.; Habu, S.; Okumura, K.; Welsh, R. M. Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo. J. Immunol. 1983, 131, 1531-1538.
38. Habu, S.; Akamatsu, I.; Tamaoki, N.; Okumura, K. In vivo significance of NK cells on resistance against virus (HSV-1) infections in mice. J. Immunol. 1984, 133, 2743-2747.
39. Roger-Zisman, B.; Quan, P. C.; Rosner, M.; Moller, J. R.; Bloom, B. R. Role of NK cells in protection of mice against herpes simplex virus-1 infection. J. Immunol. 1987, 138, 884-888.
40. March, J. C. The effects of cancer chemotherapeutic agents on normal hematopoietic precursor cells. Cancer Res. 1976, 19, 135-142.
41. Shih, W. W.; Baumhefner, R. W.; Tourtellotte, W. W.; Haskell, C. M.; Korn, E. L.; Fahey, J. L. Difference in effect of single immunosuppressive agents (cyclophosphamide, CCNU, 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis. Clin. Exp. Immunol. 1983, 53, 122-132.
42. Umeda, Y.; Sakamoto, A.; Nakamura, J.; Ishitsuka, H.; Yagi, Y. Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays. Cancer Immunol. Immuno-ther. 1983, 15, 78-83.
43. Rasi, G.; Silecchis, G.; Sinibaldi-Vallebona, P.; Spaziani, E.; Pierimaechi, P.; Sivilia, M.; Tremeterra, S.; Garaci, E. Anti-tumor effect of combined treatment with thymosin alpha 1 and inteleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Internat. J. Cancer 1994, 57, 701-705.
44. Rafique, M.; Adachi, W. Effects of intraportal administration of chemoim-munotherapeutic agents on natural killer cell activity in the rat liver. J. Surgical Oncol. 1995, 60, 154-159.
45. Kido, T.; Mori, K.; Daikuhara, H.; Tuchiya, H.; Ishige, A.; Sasaki, H. The protective effect of Hochu-ekki-to (TJ-41), a Japanese herbal medicine, against HSV-1 infection in mytomycin C-ireated mice. Anticancer Res. 2000, 20, 4109-4114.
46. Ochiai, H.; Niwayama, S.; Masuyama, K. Inhibition of experimental pulmonary metastasis in mice by β -cyclodextrin-benzaldehyde. J. Cancer Res. Clin. Oncol. 1986, 112, 216-220.
47. Elion, G. B.; Singer, S.; Hitchings, G. H. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biologically related antimetabolites. J. Biol. Chem. 1954, 208, 477-488.
48. Epstein, S. L.; Misplon, J. A.; Lawson, C. M.; Subbara, E. K.; Connors, M.; Murphy, B. R. Beta 2-microglobulin-deficient mice can be protected against influenza A injection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase. J. Immunol. 1993, 150, 5484-5493.
49. Tao, T.; Davoodi, F.; Cho, C. J.; Skiadopoulos, M. H.; Durbin, A. P.; Colins, P. L.; Murphy, B. R. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 even in animals immune to PIV3. Vaccine 2000, 18, 1359-1366.